Andrew Lam is Managing Director, Head of Biotech Private Equity at Ally Bridge Group, a global healthcare investment firm focused on high-impact life science innovation. Andrew leads ABG’s investment strategy in therapeutics with a focus on crossover-stage private biotech companies. Andrew is a clinical pharmacist by training with over two decades of therapeutics-focused professional experience spanning late-stage venture investing, investment banking, and equity research. Andrew began his career in operating roles within several biotechnology companies, including Celgene and Shire. Andrew holds a PharmD from Long Island University and an MBA from Drexel University.